Overview of common movement disorders

CONTINUUM Lifelong Learning in Neurology

Volumn 16, Issue 1, 2010, Pages 13-48

  Ostrem, Jill L ^a   Galifianakis, Nicholas B ^b  

^a ALLERGAN INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMIODARONE; ANTIEMETIC AGENT; APOMORPHINE; ATENOLOL; BACLOFEN; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; CALCIUM CHANNEL BLOCKING AGENT; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; IMMUNOSUPPRESSIVE AGENT; LITHIUM; NADOLOL; NEUROLEPTIC AGENT; NIMODIPINE; PHENYTOIN; PRIMIDONE; PROPRANOLOL; RESERPINE; SOTALOL; TETRABENAZINE; TOPIRAMATE; TRIHEXYPHENIDYL; UNINDEXED DRUG; VALPROIC ACID;

ADULT; AGED; ALERTNESS; AMNESIA; ANOREXIA; ARTICLE; ATAXIA; BEDTIME DOSAGE; BRADYCARDIA; BRADYKINESIA; BRONCHOSPASM; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL PRACTICE; COGNITIVE DEFECT; CONFUSION; COUGHING; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; DYSTONIA; ESSENTIAL TREMOR; FATIGUE; GAIT DISORDER; GENE LOCUS; GENE MUTATION; HALLUCINATION; HEADACHE; HEARTBURN; HUMAN; HYPOTENSION; IMPOTENCE; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; MUSCLE WEAKNESS; NAUSEA; NEUROLOGIC DISEASE; ONSET AGE; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PARKINSON DISEASE; PARKINSONISM; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RASH; RATING SCALE; REM SLEEP; SEDATION; SIDE EFFECT; SLEEP DISORDER; SLURRED SPEECH; SOMNOLENCE; SPASTICITY; TREATMENT RESPONSE; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; VERTIGO; WEIGHT REDUCTION; XEROSTOMIA;

EID: 78650733561     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000348899.02339.9d     Document Type: Article

References (53)

1. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001;57(3):456-462.
2. Bain P, Brin M, Deuschl G, et al. Criteria for the diagnosis of essential tremor. Neurology 2000;54(11 suppl 4):S7.
3. Bain PG, Findley LJ, Thompson PD, et al. A study of hereditary essential tremor. Brain 1994;117( pt 4):805-824.
4. Balcioglu A, Kim MO, Sharma N, et al. Dopamine release is impaired in a mouse model of DYT1 dystonia. J Neurochem 2007;102(3):783-788.
5. Benito-León J, Louis ED. Clinical update: Diagnosis and treatment of essential tremor [published erratum appears in Lancet 2007b;370(9587):566. Dosage error in article text].
6. Lancet 2007;369(9568):1152-1154.
7. Benito-Leon J, Louis ED, Bermejo-Pareja F, et al. Elderly-onset essential tremor is associated with dementia. Neurology 2006;66(10):1500-1505.
8. Benito-Leon J, Louis ED, Bermejo-Pareja F, et al. Reported hearing impairment in essential tremor: A population-based case-control study. Neuroepidemiology 2007a;29(3-4):213-217.
9. Braak H, Del Tredici K, Bratzke H, et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002;249(suppl 3):III/1-5.
10. Bressman SB. Dystonia genotypes, phenotypes, and classification. Adv Neurol 2004;94:101-107.
11. Bressman SB, de Leon D, Kramer PL, et al. Dystonia in Ashkenazi Jews: Clinical characterization of a founder mutation [published erratum appears in Ann Neurol 1995;37(1):140].
12. Ann Neurol 1994;36(5):771-777.
13. Bressman SB, Sabatti C, Raymond D, et al. The DYT1 phenotype and guidelines for diagnostic testing. Neurology 2000;54(9):1746-1752.
14. Brochard S, Remy-Neris O, Filipetti P, Bussel B. Intrathecal baclofen infusion for ambulant children with cerebral palsy. Pediatr Neurol 2009;40(4): 265-270.
15. Dahodwala N, Siderowf A, Xie M, et al. Racial differences in the diagnosis of Parkinson's disease. Mov Disord 2009;24(8):1200-1205.
16. Das SK, Banerjee TK, Roy T, et al. Prevalence of essential tremor in the city of Kolkata, India: A house-to-house survey. Eur J Neurol 2009;16(7):801-807.
17. Defazio G, Berardelli A, Abbruzzese G, et al. Risk factors for spread of primary adult onset blepharospasm: A multicentre investigation of the Italian movement disorders study group. J Neurol Neurosurg Psychiatry 1999;67(5):613-619.
18. Dobyns WB, Ozelius LJ, Kramer PL, et al. Rapid-onset dystonia- parkinsonism. Neurology 1993;43(12):2596-2602.
19. Dogu O, Sevim S, Camdeviren H, et al. Prevalence of essential tremor: Door-to-door neurologic exams in Mersin Province, Turkey. Neurology 2003;61(12):1804-1806.
20. Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 2009;72(5):432-438.
21. Elble RJ, Higgins C, Leffler K, Hughes L. Factors influencing the amplitude and frequency of essential tremor. Mov Disord 1994;9(6):589-596.
22. Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. A prevalence study of primary dystonia in eight European countries. J Neurol Neurosurg Psychiatry 2000;247(10):787-792.
23. Fahn S, Bressman SB, Marsden CD. Classification of dystonia. Adv Neurol 1998;78:1-10.
24. Findley LJ, Cleeves L, Calzetti S. Primidone in essential tremor of the hands and head: A double blind controlled clinical study. J Neurol Neurosurg Psychiatry 1985;48(9):911-915.
25. Gagnon JF, Bedard MA, Fantini ML, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002;59(4):585-589.
26. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125(pt 4):861-870.
27. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55(3):181-184.
28. Ivanhoe CB, Francisco GE, McGuire JR, et al. Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. Arch Phys Med Rehabil 2006;87(11):1509-1515.
29. Jain S, Lo SE, Louis ED. Common misdiagnosis of a common neurological disorder: how are we misdiagnosing essential tremor? Arch Neurol 2006;63(8):1100-1104.
30. Jankovic J. Treatment of dystonia. Lancet Neurol 2006;5(10):864-872.
31. Katzenschlager R, Lees AJ. Olfaction and Parkinson's syndromes: its role in differential diagnosis. Curr Opin Neurol 2004;17(4):417-423.
32. Klein C. The twists and turns of dystonia genes and loci: An update. The Movement Disorder Society web site. www.movementdisorders.org. Updated 2009 edition February/March. Accessed March 21, 2009.
33. Koller W, Biary N, Cone S. Disability in essential tremor: effect of treatment. Neurology 1986;36(7):1001-1014.
34. Koller WC, Busenbark K, Miner K. The relationship of essential tremor to other movement disorders: Report on 678 patients. Essential Tremor Study Group. Ann Neurol 1994;35(6):717-723.
35. Lou JS, Jankovic J. Essential tremor: Clinical correlates in 350 patients. Neurology 1991;41(2 (pt 1)):234-238.
36. Louis ED. Clinical practice: essential tremor. N Engl J Med 2001;345(12):887-891.
37. Louis ED, Ottman R. Study of possible factors associated with age of onset in essential tremor. Mov Disord 2006;21(11):1980-1986.
38. McLean PJ. Kawamata H, Shariff S, et al. TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem 2002;83(4):846-854.
39. Nutt JG, Muenter MD, Aronson A, et al. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988;3(3):188-194.
40. Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1991;41(2(pt 1)):174-181.
41. Ozelius LJ, Hewett JW, Page CE, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 1997;17(1):40-48.
42. Putzke JD, Whaley NR, Baba Y, et al. Essential tremor: predictors of disease progression in a clinical cohort. J Neurol Neurosurg Psychiatry 2006;77(11):1235-1237.
43. Quinn NP. Essential myoclonus and myoclonic dystonia. Mov Disord 1996;11(2):119-124.
44. Rautakorpi I, Takala J, Marttila RJ, et al. Essential tremor in a Finnish population. Acta Neurol Scand 1982;66(1):58-67.
45. Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23(2):183-189.
46. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008;63(2):167-173.
47. Singer C, Sanchez-Ramos J, Weiner WJ. Gait abnormality in essential tremor. Mov Disord 1994;9(2):193-196.
48. Tan E, Fook-Chong S, Lum SY, et al. Non-motor manifestations in essential tremor: use of a validated instrument to evaluate a wide spectrum of symptoms. Parkinsonism Relat Disord 2005;11(6):375-380.
49. Tarsy D, Simon DK. Dystonia. N Engl J Med 2006;355(8):818-829.
50. Taylor KS, Cook JA, Counsell CE. Heterogeneity in male to female risk for Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78(8):905-906.
51. Tolosa E, Gaig C, Santamaría J, Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology 2009;72(7 suppl):S12-S20.
52. Zesiewicz TA, Elble R, Louis ED, et al. Practice parameter: Therapies for essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2005;64(12):2008-2020.
53. Zimprich A, Grabowski M, Asmus F, et al. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet 2001;29(1):66-69.